MRSA
Also known as: Methicillin-resistant Staphylococcus aureus
Methodology & AI Transparency ⓘ
MRSA Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: MRSA stands for methicillin-resistant Staphylococcus aureus.
- 2 Real-world patient consensus: Diagnostic registry B95.62: MRSA is managed within Skin & Dermatology (aka Methicillin-resistant Staphylococcus aureus).
- 3 Typical cash cost range: Clinicians assessing MRSA focus on cutaneous immune skewing in MRSA (B95.62: (Th2/IL-4/IL-13 in atopic) and targeted history.
- 4 Top reported side effects / signs: Longitudinal MRSA monitoring tracks Fasting Lipids & in MRSA (B95.62: ALT (if systemic) toward Within baseline reference limits (B95.62).
Ask our AI Specialists anything about MRSA
What Is MRSA?
MRSA stands for methicillin-resistant Staphylococcus aureus. It causes a staph infection (pronounced "staff infection") that is resistant to several common antibiotics . There are two types of infection. Hospital-associated MRSA happens to people in health care settings. Community-associated MRSA happens to people who have close skin-to-skin contact with others, such as athletes involved in football and wrestling. Infection control is key to stopping MRSA in hospitals.
Pathophysiology, Underlying Causes & Clinical Presentation
In MRSA (B95.62), physiological disruption stems from cutaneous immune skewing in MRSA (B95.62: (Th2/IL-4/IL-13 in atopic), Cross-referenced with NIH MeSH (Methicillin-Resistant Staphylococcus aureus), informing Dermatology: Acne, Eczema, Psoriasis & Rosacea protocols that track 25-Hydroxy Vitamin D in MRSA (B95.62: & hs-CRP) (25(OH)D 40–65 ng/mL (B95.62)).
Common Symptoms & Clinical Signs
- • Practice good hygiene
- • Keep cuts and scrapes clean and covered with a bandage until healed
- • Presentation of MRSA (B95.62): compromised epidermal barrier in MRSA (B95.62: with dryness, fissuring,)
- • Secondary MRSA clinical sign: post-inflammatory hyperpigmentation, facial in MRSA (B95.62: flushing, or pitted)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
MRSA Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | B95.62 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Dermatology: Acne, Eczema, Psoriasis & Rosacea | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Fasting Lipids & in MRSA (B95.62: ALT (if systemic) | Within baseline reference limits (B95.62) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: 25-Hydroxy Vitamin D in MRSA (B95.62: & hs-CRP) | 25(OH)D 40–65 ng/mL (B95.62) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Affected Body Surface in MRSA (B95.62: Area (BSA /) | Clear or Almost Clear (IGA 0–1) (B95.62) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for MRSA
Treatment selection for MRSA depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (MRSA)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Acne:: What a 241-Participant Study Found In 3 clinical trials, CAB, the only fixed-dose, triple-combination applied to the skin for acne, demonstrated ≥70% lesion reductions, with good tolerability regardless of participants' sex or age. Journal of drugs in dermatology : JDD • 2026-08-01 • Phase III Randomized Trial | N = 241 | 88/100 | PMID 42555077 ↗ |
| Cost per responder analysis of abrocitinib vs. Dupilumab: Which Works Better for Moderate to severe eczema? According to JADE COMPARE trial data, the costs per responder of abrocitinib were considerably lower than dupilumab. Italian journal of dermatology and venereology • 2024-12-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 39250163 ↗ |
| Can This Approach Help? Inside the Latest Research on A gold-standard blind study of the effects of 13-cis-retinoic acid on acne, sebum The decline in micro-organisms occurred after the reduction in sebum and FFA production. The British journal of dermatology • 1982-11-15 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 6215056 ↗ |
| Stubborn Plaque Psoriasis? A Targeted New Antibody Cleared Skin in a 461-Patient Trial The real-world benefits and safety of vunakizumab are not affected by different regions of China in patients with moderate-to-severe plaque psoriasis skin flare-ups skin flare-ups. The Journal of dermatological treatment • 2025-12-15 • Phase III Randomized Trial | N = 118 | 82/100 | PMID 41020409 ↗ |
MRSA Patient Community & “People Like Me” Threads
Filter MRSA community threads and patient logs by age, biological sex, dosage, and treatment duration.